Helen Story
Family Medicine · Wheat Ridge, CONPI 1811996838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 280 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,675 and has fallen 98.8% since, to $20 in 2025. Among family medicine clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$769
- Johnson & Johnson$695
- Amgen$658
- Novo Nordisk$463
- AstraZeneca$330
- Pfizer$284
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,748100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $769 |
| Johnson & Johnson(2 entities) | 33 | $695 |
| Amgen(2 entities) | 34 | $658 |
| Novo Nordisk | 31 | $463 |
| AstraZeneca | 20 | $330 |
| Pfizer | 24 | $284 |
| Boehringer Ingelheim | 13 | $274 |
| GSK | 13 | $213 |
| Eisai Inc. | 7 | $140 |
| Merck | 8 | $124 |
| Lilly USA, LLC | 5 | $71 |
| Sanofi Pasteur Inc. | 2 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Avanir Pharmaceuticals, Inc. | 3 | $56 |
| Ironwood Pharmaceuticals, Inc | 3 | $53 |
| IBSA Pharma Inc. | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| Novartis | 3 | $45 |
| Amarin Pharma, Inc. | 3 | $39 |
| Biogen | 2 | $38 |
| Gilead | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Shire North American Group Inc | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Coopersurgical, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
How this compares
$4,771 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 34 | $53,148 |
| OzempicSemaglutide | 37 | $41,999 |
| XifaxanRifaximin | 12 | $38,135 |
| EliquisApixaban | 28 | $30,431 |
| FarxigaDapagliflozin Propanediol | 25 | $30,396 |
| JanuviaSitagliptin Phosphate | 17 | $27,824 |
| JardianceEmpagliflozin | 14 | $22,264 |
| XareltoRivaroxaban | 19 | $20,356 |
| Atrovent HfaIpratropium Bromide | 12 | $10,742 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $10,591 |
| DuleraMometasone/Formoterol | 22 | $9,392 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $9,334 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $5,531 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $5,086 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $4,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $71 | $53,14834 claims |
| Novo NordiskOzempic | $463 | $41,99937 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $30 | $38,13512 claims |
| MerckJanuvia, Dulera | $124 | $37,21639 claims |
| AstraZenecaFarxiga, Symbicort | $330 | $33,63638 claims |
| PfizerEliquis | $284 | $30,43128 claims |
| Boehringer IngelheimJardiance | $274 | $22,26414 claims |
| Johnson & JohnsonXarelto | $695 | $20,35619 claims |
| GSKIncruse Ellipta, Anoro Ellipta | $213 | $19,92535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Wheat Ridge
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.